RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx to Participate at Investor Conferences in March

Ultragenyx to Participate at Investor Conferences in March

44th Annual Cowen Healthcare Conference on March 4

Leerink Partners Global Biopharma Conference on March 12

Barclays 26th Annual Global Healthcare Conference on March 13

NOVATO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) --  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that management will be participating in three upcoming investor conferences.

44th Annual Cowen Healthcare Conference (Boston, MA)

  • Monday, March 4, 2024, Eric Crombez, M.D., Chief Medical Officer, will participate in a fireside chat and host 1x1 meetings.

Leerink Partners Global Biopharma Conference (Miami, FL)

  • Tuesday, March 12, 2024, Emil Kakkis, M.D., Ph.D., CEO and President and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1x1 meetings.

Barclays 26th Annual Global Healthcare Conference (Miami, FL)

  • Wednesday, March 13, 2024, Emil Kakkis and Howard Horn will participate in a fireside chat and host 1x1 meetings.

The live and archived webcast of the fireside chat will be accessible from the company’s website at .

About Ultragenyx

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: .

Contacts – Ultragenyx

Investors

Media



EN
27/02/2024

Underlying

RAREUltragenyx Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ultragenyx Pharmaceutical Inc.

 PRESS RELEASE
Free
RARE Ultragenyx Phar...

Ultragenyx to Participate at Investor Conferences in March

Ultragenyx to Participate at Investor Conferences in March NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in three upcoming investor conferences. 46th Annual Cowen Healthcare Conference (Boston, MA) Monday, March 2, 2026, Eric Crombez, M.D., Chief Medical Officer, will participate in a fireside chat and host 1x1 meetings. Barclays 28th Annual Global Healthcare Co...

February 23, 2026 1 EN
 PRESS RELEASE
Free
RARE Ultragenyx Phar...

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Bi...

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) PDUFA action date set for August 23, 2026 If approved, DTX401 will be the first treatment to address the underlying cause of GDSIa NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted for review the Biologics License Application (BLA) seeking approval of DTX401 AAV gene therapy (parigl...

February 23, 2026 1 EN
 PRESS RELEASE
Free
RARE Ultragenyx Phar...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NOVATO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 22,917 restricted stock units of the company’s common stock to six newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Pla...

February 20, 2026 1 EN
Wedbush Research
  • Wedbush Research
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
TRIP TRIPADVISOR INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MNKD MANNKIND CORP.
MELI MERCADOLIBRE INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EXPE EXPEDIA GROUP INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ARDX ARDELYX INC
AJX GREAT AJAX
NFLX NETFLIX INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
ZS ZSCALER INC.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
CRSR INC.
PRAX CORSAIR GAMING
TVTX PRAXIS PRECISION MEDICINES
STX TRAVERE THERAPEUTICS INC
GFS SEAGATE TECHNOLOGY HLDGS PLC
GMTX GLOBALFOUNDRIES INC
EWTX GEMINI THERAPEUTICS INC
DDI EDGEWISE THERAPEUTICS INC
EMBRAC B DOUBLEDOWN INTERACTIVE CO LTD
BCAX EMBRACER GROUP AB
TLX BICARA THERAPEUTICS INC.
VOYG TELIX PHARMACEUTICALS LIMITED
BTGO VOYAGER TECHNOLOGIES INC
BITGO HOLDINGS INC.
02/17/26 February 17, 2026 1 EN
Laura Chico ... (+2)
  • Laura Chico
  • Thomas Yip
RARE ULTRAGENYX PHARMACEUTICAL INC.
02/13/26 February 13, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch